Ignite Creation Date:
2025-12-24 @ 11:09 PM
Ignite Modification Date:
2026-01-13 @ 11:14 PM
Study NCT ID:
NCT03866369
Status:
COMPLETED
Last Update Posted:
2019-11-01
First Post:
2019-03-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose
Sponsor:
Inventiva Pharma
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-01-17
Start Date Type:
ACTUAL
Primary Completion Date:
2019-08-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-08-27
Completion Date Type:
ACTUAL
First Submit Date:
2019-03-01
First Submit QC Date:
None
Study First Post Date:
2019-03-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-10-31
Last Update Post Date:
2019-11-01
Last Update Post Date Type:
ACTUAL